產(chǎn)品詳情
  • 產(chǎn)品名稱:ClassII,MajorHistocompatibilityComplex,Transactivator(CIITA)(MiddleRegion)Pepti

  • 產(chǎn)品型號:
  • 產(chǎn)品廠商:半導(dǎo)體
  • 產(chǎn)品文檔:
你添加了1件商品 查看購物車
簡單介紹:
ClassII,MajorHistocompatibilityComplex,Transactivator(CIITA)(MiddleRegion)Peptide
詳情介紹:
Blocked Antibody anti-Class II, Major Histocompatibility Complex, Transactivator (CIITA) (Middle Region) antibody (ABIN2780332)
Characteristics This is a synthetic peptide designed for use in combination with anti-CIITA antibody (Catalog #: ARP37976_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Purification Purified
Background CIITA is a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the 'master control factor' for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction.This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the 'master control factor' for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction. Sequence Note: This RefSeq record was created from transcript and genomic sequence data because no single transcript was available for the full length of the gene. The extent of this transcript is supported by transcript alignments. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.

Alias Symbols: C2TA, CIITA IV, MHC2TA, NLRA, CIITAIV

Protein Interaction Partner: ACTB,HIST4H4,POLR2A,HDAC4,HDAC5,KAT2B,NCOA1,NFYB,PRKACA,RFX5,RFXANK,TAF6,XPO1,ZXDC,CDK1,MAPK1,MAPK3,NCOA1,RFX5,RFXANK,XPO1

Protein Size: 1130
Molecular Weight 123 kDa
Gene ID 4261
NCBI Accession NM_000246, NP_000237
UniProt P33076
Research Area Adaptive Immunity, Transcription Factors, Chromatin and Nuclear Signaling
Application Notes Each Investigator should determine their own optimal working dilution for specific applications.
Restrictions For Research Use only
Format Lyophilized
Reconstitution Add 100?μL of sterile PBS. Final peptide concentration is 1?mg/mL in PBS.
Concentration 1 mg/mL
Buffer Final peptide concentration is 1 mg/mL in PBS.
Handling Advice Avoid repeated freeze-thaw cycles.
Storage -20 °C
Storage Comment For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.